The spatial arrangement of DNA can shape the characteristics of blood cancer
Acute myeloid leukemia (AML) is a malignant disorder of the hematopoietic system in the bone marrow, affecting an early precursor stage of what are known as myeloid cells. In healthy people, these cells develop into red blood cells, platelets and some white blood cells—a process that is normally strictly regulated.
Acute myeloid leukemia (AML) is a malignant disease of the blood-forming system in the bone marrow, affecting early myeloid cells. In healthy individuals, these cells develop into blood cells like red blood cells, platelets, and some white blood cells. However, in AML patients, genetic alterations cause the cells to multiply uncontrollably, leading to a disruption of vital hematopoietic functions.
The causes of AML remain unclear and may involve various genetic changes, some acquired over time. Researchers from Kiel University, UKSH, Charité, and the Max Planck Institute for Molecular Genetics have published a study in Leukemia, investigating how two common mutations—IDH1 and DNMT3A—influence the three-dimensional organization of the genome in leukemia cells.
Both mutations interfere with DNA's spatial arrangement differently and are associated with altered activity of numerous genes, a mechanism previously unknown in AML. DNA within the cell nucleus is folded and organized spatially, allowing certain sections to come into contact, influencing gene activity. The study reveals that mutations in IDH1 and DNMT3A can also alter DNA methylation, affecting CTCF-binding proteins responsible for forming loops and reorganizing the DNA's three-dimensional structure.
Researchers identified thousands of altered DNA loops for each mutation in cell models and patient samples, with more changes correlating to more pronounced alterations in gene activity. These 3D changes result in specific alterations in gene activation and signaling pathways, unique to each mutation. In IDH1-mutated AML cells, they observed changes affecting resistance to tyrosine kinase inhibitors and immune response signaling pathways.
In DNMT3A-mutated cells, signaling pathways related to the immune response were affected. The study also found that inhibiting the IGF1R gene could be a potential treatment option for IDH1-mutated AML, with synergistic effects when combined with the IDH1 inhibitor ivosidenib. Additionally, the p38/MAPK inhibitor ralimetinib showed promise as a therapeutic option for DNMT3A-mutated AML.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.